

**October 26, 2023**

## Contents

Lab Analytes & Panels .....	2
Additions.....	2
Medications.....	2
Additions.....	2
Updates .....	3
Regimen Library.....	4
Additions.....	4
Updates .....	5
Renames .....	6
Research.....	6
Updates .....	6
Billing & HCPCS Codes .....	8
Updates .....	8

# Lab Analytes & Panels

## Additions

- EJ Ab, SI
- JO-1 AB, SI
- MDA-5 Ab, SI
- Mi-2 alpha Ab, SI
- Mi-2 beta Ab, SI
- NXP-2 Ab, SI
- OJ Ab, SI
- PL-12 Ab, SI
- PL-7 Ab, SI
- SRP Ab, SI
- TIF-1 gamma Ab, SI

# Medications

## Additions

- AAA617 (Lutetium (177Lu) vipivotide tetraxetan) invest IV
- AZD2936 invest IV
- BMF-500 invest Oral
- CJC-1295 Acetate Oral
- Ezabentlimab invest (BI 754091 invest IV)
- Gallium (68Ga) gozetotide invest (68Ga-PSMA-11 invest IV)
- HLX10 invest IV
- Ivonescimab invest IV
- Ivonescimab or pembrolizumab invest IV
- MEDI5752 invest IV
- Melanotan II Subcutaneous
- NDI-101150 invest Oral
- PHE885 invest IV
- Pirtobrutinib invest (LOXO-305 invest Oral)
- Sermorelin Acetate Subcutaneous
- Sermorelin-Ipamorelin Compound Oral
- Sermorelin-Ipamorelin Compound Subcutaneous

## Updates

Medication	Update
BI 1810631 invest Oral	<p>New <b>Forms</b> are now available:</p> <ul style="list-style-type: none"> <li>• 15 mg tablet</li> <li>• 60 mg tablet</li> </ul>
Deferasirox Oral (Jadenu)	<p>New <b>Maximum Single Dose</b> is now available:</p> <ul style="list-style-type: none"> <li>• 4200 mg</li> </ul> <p>New <b>default Sig</b> is now available:</p> <ul style="list-style-type: none"> <li>• 720 mg orally daily</li> </ul> <p>New <b>Instructions</b> are now available:</p> <ul style="list-style-type: none"> <li>• Take on an empty stomach or with a light meal (around 250 calories with less than 7% fat). Do not take with aluminum-containing antacids.</li> </ul>
Deferasirox Oral Granules (Jadenu)	<p>New <b>Maximum Single Dose</b> is now available:</p> <ul style="list-style-type: none"> <li>• 4200 mg</li> </ul> <p>New <b>default Sig</b> is now available:</p> <ul style="list-style-type: none"> <li>• 720 mg orally daily</li> </ul> <p>New <b>Instructions</b> are now available:</p> <ul style="list-style-type: none"> <li>• Sprinkle granules onto soft food (e.g. yogurt or applesauce) and take by mouth. Do not take with aluminum-containing antacids.</li> </ul>
momelotinib Oral	<p>New <b>Maximum Single Dose</b> is now available:</p> <ul style="list-style-type: none"> <li>• 200 mg</li> </ul> <p>New <b>default Sig</b> is now available:</p> <ul style="list-style-type: none"> <li>• 200 mg orally daily</li> </ul> <p>New <b>Instructions</b> are now available:</p> <ul style="list-style-type: none"> <li>• Take with or without food.</li> </ul>
motixafortide Subcutaneous	<p>New <b>Rounding Rule</b> is now available:</p> <ul style="list-style-type: none"> <li>• 1 mg</li> </ul> <p>New <b>Maximum Single Dose</b> is now available:</p> <ul style="list-style-type: none"> <li>• 188 mg</li> </ul> <p>New <b>default Sig</b> is now available:</p> <ul style="list-style-type: none"> <li>• 1.25 mg/kg subcutaneously once</li> </ul> <p>New <b>Instructions</b> are now available:</p> <ul style="list-style-type: none"> <li>• Refer to prescribing information for recommendations for premedications, dosing, and administration. Filgrastim product must be administered on Days 1-4 prior to administration of motixafortide on the evening of Day 4. Calculate dose using actual body weight. Administer via slow subcutaneous injection (over approximately 2 minutes) 10 to 14 hours prior to initiation of apheresis. Injection volume should not exceed 2 mL. Divide doses requiring greater than 2 mL equally into multiple syringes. Inject into the</li> </ul>

Medication	Update
	abdomen, the back or side of upper arms, or thigh. If injecting into the abdomen, avoid a 5 cm diameter circle around the navel. If multiple injections are required, injection sites should be at least 2 cm apart. Do not inject into scar tissue or areas where the skin is reddened, inflamed, or swollen. Observe patient for 1 hour after administration.
Narazaciclib invest (ON 123300 invest Oral)	New <b>Forms</b> are now available: <ul style="list-style-type: none"> <li>• 40 mg tablet</li> <li>• 120 mg tablet</li> </ul>
Nivolumab-Relatlimab-rmbw IV 240 mg-80 mg/20 mL	New <b>Sigs</b> are now available: <ul style="list-style-type: none"> <li>• 160 mg intravenously Piggyback once</li> <li>• 160 mg intravenously Piggyback As Directed</li> <li>• 480 mg intravenously Piggyback once</li> <li>• 480 mg intravenously Piggyback As Directed</li> </ul> New <b>Default Sig</b> is now available: <ul style="list-style-type: none"> <li>• 480 mg intravenously Piggyback once</li> </ul>
NUV-868 invest Oral	New <b>Forms</b> are now available: <ul style="list-style-type: none"> <li>• 40 mg tablet</li> <li>• 160 mg tablet</li> </ul>
Quaratusugene ozeplasmid invest (GPX-001 invest IV)	New <b>Forms</b> are now available: <ul style="list-style-type: none"> <li>• 0.675 mg/1.5 mL solution</li> </ul>
TH1902 invest IV	New <b>Unit</b> is now available: <ul style="list-style-type: none"> <li>• Mg/kg</li> </ul>

## Regimen Library

### Additions

Regimen Name	Diagnosis
Daratumumab IV + Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Daratumumab IV + Lenalidomide D1-21 Q28D (Post-Transplant Maintenance)	Multiple Myeloma (MM)
Daratumumab SQ + Ixazomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Daratumumab SQ + Lenalidomide D1-21 Q28D (Post-Transplant Maintenance)	Multiple Myeloma (MM)

Regimen Name	Diagnosis
Fulvestrant (Q28D) + Trastuzumab IV (Q21D) Q84D	Breast Cancer
Fulvestrant Q28D (Uterine)	Uterine Cancer (Parent)
Megestrol Q30D (Uterine)	Uterine Cancer (Parent)
Momelotinib Q30D	Myelofibrosis
Motixafortide D4 + Filgrastim D1-5	Multiple Myeloma
Nadofaragene firadenovec-vncg (Intravesical) Q90D	Bladder Cancer
Nivolumab + Gemcitabine D1,8 + Cisplatin Q21D (Neoadjuvant NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Nivolumab D1,15,29 + Ipilimumab Q42D (Perioperative Esophageal, Gastric)	Esophageal Cancer (Parent); Gastric Cancer
Nivolumab Q28D (Flat Dose) (Perioperative Esophageal, Gastric)	Esophageal Cancer (Parent); Gastric Cancer
Panitumumab D1,15 + Adagrasib Q28D	Colon Cancer; Rectal Cancer
Panitumumab D1,15 + Sotorasib Q28D	Colon Cancer; Rectal Cancer
Pembrolizumab (Dose Banding) + Abraxane + Carboplatin Q42D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab (Dose Banding) + Pemetrexed + Cisplatin Q42D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab + Gemcitabine D1,8 + Cisplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Pembrolizumab Q21D (Flat Dose) (Perioperative NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Tremelimumab-actl D1 + Durvalumab D1,29,57 (Esophageal, Gastric)	Esophageal Cancer (Parent); Gastric Cancer

## Updates

### Antiemetic Prophylaxis

To improve ease of ordering antiemetic prophylaxis, a prechecked prescription order for oral ondansetron will be included in all regimens containing a moderate to high emetic risk oral oncolytic agent, per NCCN Guidelines. As an exception, oral oncolytic agents with risk for QT prolongation and therefore potential additive toxicity with ondansetron, will not have ondansetron prechecked. This month will conclude applicable updates.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- Amyloidosis
- Bladder Cancer
- Breast Cancer
- Esophageal Cancer (Parent)
- Fallopian Tube Cancer
- Gastric Cancer
- Leukemia, Acute Myeloid (AML)
- Lung Cancer, Non-small Cell (NSCLC)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma (MM)
- Ovarian and Primary Peritoneal Cancer
- Prostate Cancer
- Renal Pelvis and Ureter Cancer
- Urethral Cancer

## Renames

Previous Name	New Name
Cytarabine + Daunorubicin + Midostaurin Induction	Cytarabine CIV D1-7 + Daunorubicin D1-3 + Midostaurin D8-21 (Induction) Q28D
Megestrol Q30D	Megestrol Q30D (Breast)

## Research

### Updates

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 18283	X	X	X	

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 19062			<p>No longer available:            USOR 19062 Safety Run-In Tazemetostat BID Maintenance            USOR 19062 Tazemetostat or Placebo BID + Lenalidomide D1-21 + Rituximab IV BIOSIMILAR Q28D            USOR 19062 Tazemetostat or Placebo BID + Lenalidomide D1-21 + Rituximab IV Q28D Reference</p> <p>Now available:            USOR 19062 Tazemetostat or Placebo BID + Lenalidomide D1-21 + Rituximab IV Q28D</p>	
USOR 20270	X	X	<p>No longer available:            USOR 20270 Pemetrexed Premedications            USOR 20270 Pembrolizumab + Pemetrexed + Cisplatin Q21D            USOR 20270 Pembrolizumab + Pemetrexed + Carboplatin Q21D            USOR 20270 Pembrolizumab + Pemetrexed Maintenance Q21D            USOR 20270 Pembrolizumab + Pemetrexed D1,22 Maintenance Q42D            USOR 20270 MRTX849 (PO; BID) Monotherapy</p> <p>Now available:            USOR 20270 Pembrolizumab Q21D            USOR 20270 Pembrolizumab Q42D</p>	
USOR 20423	X	X	X	
USOR 21326	X	X		<p>Now available:            USOR 21326 Part 2 Bemarituzumab or Placebo + Nivolumab + CAPOX Q21D</p>
USOR 22166	X	X	X	
USOR 22181	X	X		
USOR 22232	X	X	X	
USOR 22252	X	X		
USOR 23007	X	X	X	
USOR 23031		X		

# Billing & HCPCS Codes

## Updates

Medication	HCPCS Codes
Donislecel-jujn (Lantidra)	J3590 per 4500 EIN
Motixafortide (Aphexda)	J3490 per 1.25 mg